U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C30H35BrN12O5.ClH
Molecular Weight 760.041
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BROSTALLICIN HYDROCHLORIDE

SMILES

Cl.CN1C=C(NC(=O)C2=CC(NC(=O)C3=CC(NC(=O)C4=CC(NC(=O)C(Br)=C)=CN4C)=CN3C)=CN2C)C=C1C(=O)NCCNC(N)=N

InChI

InChIKey=IPKHXIAPPAKHTB-UHFFFAOYSA-N
InChI=1S/C30H35BrN12O5.ClH/c1-16(31)25(44)36-17-9-22(41(3)12-17)27(46)38-19-11-24(43(5)14-19)29(48)39-20-10-23(42(4)15-20)28(47)37-18-8-21(40(2)13-18)26(45)34-6-7-35-30(32)33;/h8-15H,1,6-7H2,2-5H3,(H,34,45)(H,36,44)(H,37,47)(H,38,46)(H,39,48)(H4,32,33,35);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C30H35BrN12O5
Molecular Weight 723.58
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Brostallicin is a DNA minor groove binder which has shown very promising preclinical activity against a variety of human tumors both in vitro and in vivo. Brostallicin shows potent in vitro cytotoxic activity against tumor cells with IC50 values in the low nanomolar range, circumvents resistance to alkylating agents and camptothecins. Brostallicin has broad antitumor activity in animal models. A clear therapeutic gain is observed in preclinical models when brostallicin is combined with anticancer agents such as cisplatin, doxorubicin, and taxotere.

Approval Year

PubMed

PubMed

TitleDatePubMed
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
2014 Jan
Patents

Patents

Sample Use Guides

maximum tolerated doses were: 10 mg/m2 in the q3w; 2.4 mg/m2 /week in the the q1w
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:59:14 GMT 2023
Edited
by admin
on Fri Dec 15 17:59:14 GMT 2023
Record UNII
1DKC476797
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BROSTALLICIN HYDROCHLORIDE
MI  
Common Name English
PNU-166196
Code English
PNU 166196
Code English
BROSTALLICIN HYDROCHLORIDE [MI]
Common Name English
4-(2-BROMOACRYLAMIDO)-N'''-(2-GUANIDINOETHYL)-1,1',1'',1'''-TETRAMETHYL-N,4':N',4'':N'',4'''-QUATER(PYRROLE-2-CARBOXAMIDE) HYDROCHLORIDE
Common Name English
Code System Code Type Description
PUBCHEM
6918407
Created by admin on Fri Dec 15 17:59:14 GMT 2023 , Edited by admin on Fri Dec 15 17:59:14 GMT 2023
PRIMARY
FDA UNII
1DKC476797
Created by admin on Fri Dec 15 17:59:14 GMT 2023 , Edited by admin on Fri Dec 15 17:59:14 GMT 2023
PRIMARY
NCI_THESAURUS
C128040
Created by admin on Fri Dec 15 17:59:14 GMT 2023 , Edited by admin on Fri Dec 15 17:59:14 GMT 2023
PRIMARY
EPA CompTox
DTXSID10174221
Created by admin on Fri Dec 15 17:59:14 GMT 2023 , Edited by admin on Fri Dec 15 17:59:14 GMT 2023
PRIMARY
MERCK INDEX
m2728
Created by admin on Fri Dec 15 17:59:14 GMT 2023 , Edited by admin on Fri Dec 15 17:59:14 GMT 2023
PRIMARY Merck Index
DRUG BANK
DBSALT002027
Created by admin on Fri Dec 15 17:59:14 GMT 2023 , Edited by admin on Fri Dec 15 17:59:14 GMT 2023
PRIMARY
CAS
203258-38-2
Created by admin on Fri Dec 15 17:59:14 GMT 2023 , Edited by admin on Fri Dec 15 17:59:14 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY